Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

15:06
10/09/16
10/09
15:06
10/09/16
15:06

Bristol-Myers reports CheckMate-275 data on Opdivo in urothelial cancer

Bristol-Myers Squibb announced results from the CheckMate -275 trial, in which Opdivo had a confirmed objective response rate, the primary endpoint, of 19.6% in platinum-refractory patients with metastatic urothelial carcinoma. Responses were observed in both PD-L1 expressors and non-expressors. The confirmed ORR in patients expressing PD-L1 greater than or equal to 1% was 23.8%, and 16.1% in patients expressing PD-L1 less than 1%. In patients expressing PD-L1 greater than or equal to 5%, the confirmed ORR was 28.4%, and 15.8% in patients expressing PD-L1 less than 5%. The median duration of response was not reached in the overall population with a minimum follow-up of six months, and responses were ongoing in 77% of patients. Among the 52 patients who responded to treatment, the median time to a response was 1.9 months. The median PFS was 2.0 months in all treated patients, 1.87 months for patients with PD-L1 less than 1%, and 3.55 months in patients with PD-L1 greater than or equal to 1%. The median OS was 8.74 months in all treated patients, 5.95 months in patients with PD-L1 less than 1%, and 11.3 months in patients with PD-L1 expression greater than or equal to 1%. The safety profile of Opdivo in this study was consistent with the safety profile of Opdivo in other tumor types. Overall, 4.8% of patients discontinued therapy due to treatment-related AEs of any grade, and 3.0% discontinued therapy due to grade 3-4 treatment-related AEs. The data will be presented at the 2016 European Society for Medical Oncology Congress.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$81.29

6.92 (9.30%)

, BBY

Best Buy

$42.01

-2.12 (-4.80%)

13:05
03/01/17
03/01
13:05
03/01/17
13:05
General news
On The Fly: Top stock stories at midday »

Stocks opened sharply…

LOW

Lowe's

$81.29

6.92 (9.30%)

BBY

Best Buy

$42.01

-2.12 (-4.80%)

KMX

CarMax

$65.22

0.68 (1.05%)

MCD

McDonald's

$129.21

1.5608 (1.22%)

GOOG

Alphabet

$823.21

-6.07 (-0.73%)

GOOGL

Alphabet Class A

$844.93

-4.74 (-0.56%)

CMCSA

Comcast

$37.42

-0.11 (-0.29%)

CMCSK

Comcast

FOX

21st Century Fox

$29.35

-0.66 (-2.20%)

CBS

CBS

$67.48

1.56 (2.37%)

DIS

Disney

$111.73

1.635 (1.49%)

LOGM

LogMeln

$91.75

-2 (-2.13%)

FOLD

Amicus

$6.49

0.06 (0.93%)

WTW

Weight Watchers

$18.74

4.35 (30.23%)

PANW

Palo Alto Networks

$118.06

-33.84 (-22.28%)

AMBA

Ambarella

$58.95

-0.83 (-1.39%)

ETSY

Etsy

$12.12

-0.67 (-5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 19

    Mar

  • 20

    Mar

  • 04

    Apr

  • 05

    Apr

TGT

Target

$57.94

-0.8346 (-1.42%)

, AAPL

Apple

$136.99

0.06 (0.04%)

13:02
03/01/17
03/01
13:02
03/01/17
13:02
Periodicals
Target returns some iPhone SE stock ahead of Apple press event, MacRumors says »

Target (TGT) told its…

TGT

Target

$57.94

-0.8346 (-1.42%)

AAPL

Apple

$136.99

0.06 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 19

    Mar

CMTL

Comtech

$11.41

-0.37 (-3.14%)

13:02
03/01/17
03/01
13:02
03/01/17
13:02
Hot Stocks
Comtech in $4.5M pact for navigation, telematics services »

Comtech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRA

Vera Bradley

$10.46

-0.36 (-3.33%)

13:01
03/01/17
03/01
13:01
03/01/17
13:01
Options
Earnings hedge in Vera Bradley »

Earnings hedge in Vera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SKLN

Skyline Medical

$1.92

0.07 (3.78%)

12:57
03/01/17
03/01
12:57
03/01/17
12:57
Technical Analysis
Skyline Medical spikes higher on extremely heavy volume, retraces some gains »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

$1.92

0.07 (3.78%)

12:52
03/01/17
03/01
12:52
03/01/17
12:52
Hot Stocks
Skyline Medical soars after receiving contract from Vizient »

Skyline Medical has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNT

Kornit Digital

$16.20

-0.55 (-3.28%)

12:50
03/01/17
03/01
12:50
03/01/17
12:50
Conference/Events
Kornit Digital management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 02

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

TWTR

Twitter

$15.69

-0.085 (-0.54%)

12:49
03/01/17
03/01
12:49
03/01/17
12:49
Hot Stocks
Twitter says launching algorithm-based safety tools »

Twitter announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 19

    Mar

WLL

Whiting Petroleum

$11.32

0.47 (4.33%)

12:47
03/01/17
03/01
12:47
03/01/17
12:47
Conference/Events
Whiting Petroleum management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

12:45
03/01/17
03/01
12:45
03/01/17
12:45
General news
Atlanta Fed's Q1 GDPNow estimate was slashed to 1.8% »

Atlanta Fed's Q1…

PNW

Pinnacle West

$82.08

-0.11 (-0.13%)

12:44
03/01/17
03/01
12:44
03/01/17
12:44
Hot Stocks
APS, group reach consensus rate review agreement »

Arizona Public Service, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCC

Ares Capital

$17.75

-0.04 (-0.22%)

12:41
03/01/17
03/01
12:41
03/01/17
12:41
Options
Ares Capital attracts a large spread trade »

Ares Capital attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMSI

Merit Medical

$30.80

-0.05 (-0.16%)

12:37
03/01/17
03/01
12:37
03/01/17
12:37
Conference/Events
Merit Medical management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 14

    Mar

MSG

Madison Square Garden

$185.32

5.96 (3.32%)

12:36
03/01/17
03/01
12:36
03/01/17
12:36
Hot Stocks
Madison Square Garden in 'active' talks to bring Grammys back to MSG »

The Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$118.56

-33.34 (-21.95%)

12:33
03/01/17
03/01
12:33
03/01/17
12:33
Downgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 05

    Mar

IBKR

Interactive Brokers

$36.71

-0.98 (-2.60%)

12:32
03/01/17
03/01
12:32
03/01/17
12:32
Hot Stocks
Interactive Brokers reports February DARTS down 12% y/y »

Interactive Brokers Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$17.38

0.06 (0.35%)

12:32
03/01/17
03/01
12:32
03/01/17
12:32
Hot Stocks
Square acquires OrderAhead pickup business »

Square announced earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWFT

Swift Transportation

$22.13

0.41 (1.89%)

12:31
03/01/17
03/01
12:31
03/01/17
12:31
Options
Second day of bullish flow in Swift Transportation »

Second day of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$398.84

11.38 (2.94%)

, WETF

WisdomTree

$9.11

-0.21 (-2.25%)

12:31
03/01/17
03/01
12:31
03/01/17
12:31
Hot Stocks
Labor Department proposes extension of fiduciary rule applicability dates »

The U.S. Department of…

BLK

BlackRock

$398.84

11.38 (2.94%)

WETF

WisdomTree

$9.11

-0.21 (-2.25%)

LM

Legg Mason

$37.70

-0.02 (-0.05%)

IVZ

Invesco

$32.64

0.45 (1.40%)

WDR

Waddell & Reed

$19.66

0.415 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 12

    Apr

  • 11

    May

MCD

McDonald's

$128.07

0.42 (0.33%)

12:26
03/01/17
03/01
12:26
03/01/17
12:26
Technical Analysis
McDonald's trades higher following lift of halt »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MCD

McDonald's

$128.07

0.42 (0.33%)

12:25
03/01/17
03/01
12:25
03/01/17
12:25
Hot Stocks
Breaking Hot Stocks news story on McDonald's »

McDonald's up 1.4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MSFT

Microsoft

$63.98

-0.25 (-0.39%)

, FCN

FTI Consulting

$41.21

0.97 (2.41%)

12:25
03/01/17
03/01
12:25
03/01/17
12:25
Conference/Events
FTI Consulting co-hosts a webinar with Microsoft »

Webinar entitled,…

MSFT

Microsoft

$63.98

-0.25 (-0.39%)

FCN

FTI Consulting

$41.21

0.97 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 02

    Mar

  • 14

    Mar

  • 09

    May

MYL

Mylan

$41.85

-0.59 (-1.39%)

12:25
03/01/17
03/01
12:25
03/01/17
12:25
Conference/Events
Mylan to host investor day with a conference call hook-up »

CEO Bresch holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 28

    Mar

  • 03

    Sep

  • 09

    Oct

MCD

McDonald's

$128.07

0.42 (0.33%)

12:23
03/01/17
03/01
12:23
03/01/17
12:23
Hot Stocks
Breaking Hot Stocks news story on McDonald's »

McDonald's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

ANF

Abercrombie & Fitch

$11.20

-0.565 (-4.80%)

12:21
03/01/17
03/01
12:21
03/01/17
12:21
Options
Abercrombie puts outpace calls 3:1 as shares fall before earnings »

Abercrombie puts outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.